Latest news with #HearPro
Time of India
2 days ago
- Politics
- Time of India
Jaleel accuses Shirsat of acquiring multi-crore land at cheap rates, hands over docus to opposition leader Danve
Chhatrapati Sambhajinagar: All India Majlis-E-Ittehadul Muslimeen ( AIMIM ) state president and Aurangabad MP Imtiaz Jaleel on Thursday accused Maharashtra minister and Dharashiv guardian minister Sanjay Shirsat of buying land worth crores of rupees at throwaway prices. Jaleel claimed the questionable deals were indicative of larger irregularities involving the misuse of political power and manipulation of land rates. During the day, the MP also wrote a letter to chief minister Devendra Fadnavis to seek an appointment for handing him over a set of documents in the case to him. Jaleel also submitted a set of land deal documents to Ambadas Danve, the leader of opposition in the Maharashtra Legislative Council. "We will bring this issue to the notice of the governor and raise it in the upcoming assembly session," Danve said, while assuring that the documents provided by Jaleel would be thoroughly examined and the matter would be pursued through appropriate legislative channels. According to Jaleel, Shirsat allegedly acquired multiple land parcels at prices significantly lower than their actual market value over the past few years. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Toulouse: Nous recherchons des personnes pour tester les nouvelles aides auditives HearPro En savoir plus Undo "Several plots were purchased either in his name or under the names of his close relatives. One such illegal land purchase was made in the name of his son," Jaleel alleged. He also raised questions over the vehicles used by the minister. "One of the cars used by Shirsat was imported from Dubai, but was not registered in his name. The vehicle officially listed under his name is different. Where did the rest of the vehicles come from? What is the source of funds?" he asked. Shirsat, when approached for a reaction, said, "Nothing will come out of these accusations." He declined to comment further. Jaleel also took a dig at state govt, suggesting selective inaction. "I have seen Danve work against injustice over the years. This case, involving the guardian minister and this district, is no different. Earlier, in the hotel land deal matter, the CM should have ordered an inquiry. Now, looking at the pace at which new properties are being acquired by Shirsat, it seems that the 'khoke' (cash boxes) may have run out, but the collection is still going on," Jaleel said. Follow more information on Air India plane crash in Ahmedabad here . Get real-time live updates on rescue operations and check full list of passengers onboard AI 171 .
Time of India
2 days ago
- Health
- Time of India
Bharat Biotech in-licences GSK's Shigella vaccine
Hyderabad: Vaccine maker Bharat Biotech International Limited (BBIL) has in-licensed pharma giant GSK's under development Shigella vaccine candidate, altSonflex1-2-3. The vaccine candidate was being developed by GSK against Shigellosis, a severe form of bacterial diarrhoea that largely affects children aged below five years in low- and middle-income countries. While GSK has already conducted Phase I and II trials in Europe and Africa, Bharat Biotech will take up further development with Phase III clinical trials, regulatory advancement, and large-scale manufacturing, the Hyderabad-based vaccine maker said on Thursday. As part of the agreement, GSK will continue to support the programme by assisting with clinical trial design, securing external funding, and contributing to the access and delivery plans and commercialisation strategy. The vaccine has been developed on the innovative generalised modules for membrane antigens (GMMA) based platform, which uses bacterial outer membranes to deliver the O Antigen to the immune system. "The in-licensed candidate, altSonflex1-2-3, already showed encouraging results in early-stage clinical trials. A Phase 1 study conducted in Europe demonstrated a favourable safety profile and strong immune response," Bharat Biotech said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Toulouse: Nous recherchons des personnes pour tester les nouvelles aides auditives HearPro En savoir plus Undo "Subsequent Phase 2 trials in Africa, including vaccination of 9-month-old infants—the primary target population—reported no safety concerns. Interim results from 2024 confirmed that the candidate met its pre-set immunogenicity goals," it added. Bharat Biotech Executive Chairman Dr Krishna Ella said: "With no approved vaccine currently available for Shigella and antimicrobial resistance on the rise, there is an urgent need for scalable, science-backed solutions focused on low and middle-income countries. This collaboration combines our strengths in innovation, manufacturing, and global health commitment." He pointed out that Bharat Biotech already has a significant presence in vaccines for diarrhoeal infections, including rotavirus, typhoid, polio, non-typhoidal salmonella, cholera, and paratyphi. In 2021, GSK had inked a product transfer agreement for the world's first malaria vaccine, RTS,S, with Bharat Biotech. Follow more information on Air India plane crash in Ahmedabad here . Get real-time live updates on rescue operations and check full list of passengers onboard AI 171 .
